Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence

Laura A. Johnson; Luis Sanchez-Perez; Carter M. Suryadevara; John H. Sampson

doi:10.4161/21624011.2014.944059

Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence

Laura A. Johnson, Luis Sanchez-Perez, Carter M. Suryadevara, John H. Sampson

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.

Original language	English
Article number	e944059
Journal	OncoImmunology
Volume	3
Issue number	7
DOIs	https://doi.org/10.4161/21624011.2014.944059
State	Published - 2014
Externally published	Yes

Keywords

Adoptive cell therapy
Cancer immunology
Chimeric antigen receptor
Gene-engineering
Glioblastoma
Tumor immunotherapy

Access to Document

10.4161/21624011.2014.944059

Cite this

@article{0776c9c47df84332851b7bfbe352aa23,

title = "Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence",

abstract = "CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.",

keywords = "Adoptive cell therapy, Cancer immunology, Chimeric antigen receptor, Gene-engineering, Glioblastoma, Tumor immunotherapy",

author = "Johnson, {Laura A.} and Luis Sanchez-Perez and Suryadevara, {Carter M.} and Sampson, {John H.}",

note = "Publisher Copyright: {\textcopyright} 2014 Taylor & Francis Group, LLC.",

year = "2014",

doi = "10.4161/21624011.2014.944059",

language = "English",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "7",

}

TY - JOUR

T1 - Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence

AU - Johnson, Laura A.

AU - Sanchez-Perez, Luis

AU - Suryadevara, Carter M.

AU - Sampson, John H.

PY - 2014

Y1 - 2014

N2 - CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.

AB - CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.

KW - Adoptive cell therapy

KW - Cancer immunology

KW - Chimeric antigen receptor

KW - Gene-engineering

KW - Glioblastoma

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84911391219&partnerID=8YFLogxK

U2 - 10.4161/21624011.2014.944059

DO - 10.4161/21624011.2014.944059

M3 - Article

AN - SCOPUS:84911391219

VL - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 7

M1 - e944059

ER -

Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence

Abstract

Keywords

Access to Document

Fingerprint

Cite this